Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company, announced that CEO Pete Salzmann will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, 2022. The chat is scheduled for February 16 at 11:20 AM ET. Investors can access the webcast via the Investor Relations section of Immunovant's website. The company focuses on developing batoclimab, a monoclonal antibody aimed at treating autoimmune diseases driven by pathogenic IgG antibodies.

NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14 - 18, 2022.

11th Annual SVB Leerink Global Healthcare Conference
Date:			Wednesday, February 16th, 2022
Time:			11:20am Eastern Time
Webcast:			The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com

About Immunovant, Inc. 

Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing batoclimab, formerly referred to as IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. 

Contact:

Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com

FAQ

When will Immunovant CEO Pete Salzmann speak at the SVB Leerink Global Healthcare Conference?

Pete Salzmann will speak on February 16, 2022, at 11:20 AM ET.

Where can I watch the Immunovant presentation at the conference?

The presentation will be available via webcast on Immunovant's Investor Relations website.

What is batoclimab and its purpose?

Batoclimab (formerly IMVT-1401) is a fully human monoclonal antibody developed by Immunovant for treating autoimmune diseases caused by pathogenic IgG antibodies.

What is the focus of Immunovant as a biopharmaceutical company?

Immunovant focuses on enabling normal lives for individuals suffering from autoimmune diseases.